Vivoryon Therapeutics N.V. (VVY.AS)

EUR 1.9

(-1.04%)

Operating Expenses Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual operating expenses in 2023 was 24.69 Million EUR , down -9.85% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly operating expenses in 2024 Q2 was 13.8 Million EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported a annual operating expenses of 28.97 Million EUR in annual operating expenses 2022, up 32.68% from previous year.
  • Vivoryon Therapeutics N.V. reported a annual operating expenses of 21.83 Million EUR in annual operating expenses 2021, up 37.58% from previous year.
  • Vivoryon Therapeutics N.V. reported a quarterly operating expenses of 26.11 Million EUR for 2023 FY, down -9.85% from previous quarter.
  • Vivoryon Therapeutics N.V. reported a quarterly operating expenses of 10.61 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Operating Expenses of Vivoryon Therapeutics N.V. (2023 - 2011)

Year Operating Expenses Operating Expenses Growth
2023 24.69 Million EUR -9.85%
2022 28.97 Million EUR 32.68%
2021 21.83 Million EUR 37.58%
2020 15.87 Million EUR 106.49%
2019 7.68 Million EUR -0.23%
2018 7.7 Million EUR -21.86%
2017 9.85 Million EUR -28.37%
2016 13.76 Million EUR 2.85%
2015 13.38 Million EUR 18.76%
2014 11.26 Million EUR 16.74%
2013 9.65 Million EUR -8.64%
2012 10.56 Million EUR -26.07%
2011 14.29 Million EUR 0.0%

Peer Operating Expenses Comparison of Vivoryon Therapeutics N.V.

Name Operating Expenses Operating Expenses Difference
ABIONYX Pharma SA 4.17 Million EUR -491.142%
ABIVAX Société Anonyme 127.37 Million EUR 80.615%
Adocia SA 15.62 Million EUR -57.988%
Aelis Farma SA 18.81 Million EUR -31.208%
Biophytis S.A. 14.33 Million EUR -72.274%
Advicenne S.A. 8.21 Million EUR -200.572%
genOway Société anonyme 16.73 Million EUR -47.518%
IntegraGen SA 5.35 Million EUR -361.316%
Medesis Pharma S.A. 1.56 Million EUR -1478.195%
Neovacs S.A. 10.34 Million EUR -138.719%
NFL Biosciences SA 4.37 Million EUR -464.472%
Plant Advanced Technologies SA 2.76 Million EUR -793.068%
Quantum Genomics Société Anonyme 1.71 Million EUR -1337.282%
Sensorion SA 27.05 Million EUR 8.73%
Theranexus Société Anonyme 3 Million EUR -721.701%
TME Pharma N.V. 5.49 Million EUR -349.19%
Valbiotis SA 9.86 Million EUR -150.198%
TheraVet SA 1.64 Million EUR -1401.661%
Valerio Therapeutics Société anonyme 20.32 Million EUR -21.516%
argenx SE 1.34 Billion EUR 98.161%
BioSenic S.A. 7.58 Million EUR -225.623%
Celyad Oncology SA 8.49 Million EUR -190.836%
DBV Technologies S.A. 89.4 Million EUR 72.382%
Galapagos NV 327.98 Million EUR 92.472%
Genfit S.A. 54.8 Million EUR 54.945%
GeNeuro SA 14.35 Million EUR -71.982%
Hyloris Pharmaceuticals SA 17.98 Million EUR -37.277%
Innate Pharma S.A. 64.57 Million EUR 61.759%
Inventiva S.A. 120.18 Million EUR 79.455%
MaaT Pharma SA 21.59 Million EUR -14.325%
MedinCell S.A. 32.92 Million EUR 24.998%
Nanobiotix S.A. 58.92 Million EUR 58.097%
Onward Medical N.V. 20.64 Million EUR -19.603%
Oryzon Genomics S.A. 18.49 Million EUR -33.491%
OSE Immunotherapeutics SA 23.58 Million EUR -4.676%
Oxurion NV 12.21 Million EUR -102.161%
Pharming Group N.V. 204.24 Million EUR 87.911%
Poxel S.A. 28.76 Million EUR 14.16%
GenSight Biologics S.A. 32.66 Million EUR 24.397%
Transgene SA 31.23 Million EUR 20.938%
Financière de Tubize SA 114.38 Thousand EUR -21485.992%
UCB SA 2.94 Billion EUR 99.16%
Valneva SE 134.92 Million EUR 81.699%